Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Cancer

STK36: a potential prognostic biomarker in hepatocellular carcinoma

4 affiliations
  1. 1Department of Pathology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing, 100015 China
  2. 2Department of Neurosurgery, the Fourth Medical Center of PLA General Hospital, Beijing, China
  3. 3Department of Cardiovascular Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing, 100015 China
  4. 4Department of Pathology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000 China

Abstract

Background: STK36, a member of the serine/threonine kinase family, has been reported to be highly expressed in cancers. However, there have been fewer reports on the expression and role of STK36 in hepatocellular carcinoma (HCC).

Methods: We used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to evaluate the differential expression of STK36 in HCC and normal tissues. Immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction(qRT-PCR) validated the expression of STK36 in HCC. The chi-square test was employed to study the relationship between STK36 and clinical characteristics. The prognostic significance of STK36 expression was analyzed using Kaplan-Meier and Cox regression methods. We also studied the association between STK36 and immunity. We discussed STK36 expression at the single-cell and spatial transcriptome distribution levels. Drug sensitivity analysis was utilized to discuss the link between STK36 expression and small-molecule drugs. Gene Set Enrichment Analysis (GSEA) was used to discuss the function of STK36 in HCC.

Results: STK36 expression was elevated in HCC from the TCGA and ICGC databases. IHC and qRT-PCR confirmed the overexpression of STK36 in HCC. STK36 expression had a positive correlation with T stage (tumor stage). STK36 expression was an independent prognostic factor affecting HCC patients’ outcomes. A relationship existed between STK36 expression and the infiltration of immune cells as well as immune checkpoints. Single-cell and spatial transcriptome analyses demonstrated that STK36 was upregulated in HCC. GSEA showed that STK36 was involved in some pathways, including ECM-receptor interaction, cell cycle, etc.

Conclusion: STK36 acts as a potential prognostic index in HCC, serves as a potential biomarker for predicting response to immunotherapy, and provides a rationale for further functional studies.

Related

  1. Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis
    Yuliya V. Perfilyeva, Nurshat Abdolla, Aikyn Kali +4
    Future OncologyPeer-reviewedLicence not statedFull textClinical trials & evidence synthesisPMC
  2. BRIX1 Promotes Hepatocellular Carcinoma Progression via the MAPK/ERK Pathway and Serves as a Prognostic Biomarker
    X. Pan, x. Wang, Y. Zhou
    bioRxivPreprintCC BYFull textOncologybioRxiv
  3. Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
    Pengfei Chen, Kangmei Tong, Lisheng You +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma
    Wu Yaoyao, Lin Qingfeng, Huang Liyou +3
    Scientific ReportsPeer-reviewedCC BYFull textOncologyDOAJ
  5. Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
BibTeX
@article{liu2026stk36,
  title = {{STK36: a potential prognostic biomarker in hepatocellular carcinoma}},
  author = {Ting Liu and Yanyong Ma and Zhizhao Li and Xuan Zhou},
  journal = {BMC Cancer},
  year = {2026},
  month = aug,
  doi = {10.1186/s12885-026-16691-y},
  url = {https://doi.org/10.1186/s12885-026-16691-y},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - STK36: a potential prognostic biomarker in hepatocellular carcinoma
AU  - Ting Liu
AU  - Yanyong Ma
AU  - Zhizhao Li
AU  - Xuan Zhou
PY  - 2026
DA  - 2026/08/10
JO  - BMC Cancer
DO  - 10.1186/s12885-026-16691-y
UR  - https://doi.org/10.1186/s12885-026-16691-y
AB  - Background: STK36, a member of the serine/threonine kinase family, has been reported to be highly expressed in cancers. However, there have been fewer reports on the expression and role of STK36 in hepatocellular carcinoma (HCC).  Methods: We used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to evaluate the differential expression of STK36 in HCC and normal tissues. Immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction(qRT-PCR) validated the expression of STK36 in HCC. The chi-square test was employed to study the relationship between STK36 and clinical characteristics. The prognostic significance of STK36 expression was analyzed using Kaplan-Meier and Cox regression methods. We also studied the association between STK36 and immunity. We discussed STK36 expression at the single-cell and spatial transcriptome distribution levels. Drug sensitivity analysis was utilized to discuss the link between STK36 expression and small-molecule drugs. Gene Set Enrichment Analysis (GSEA) was used to discuss the function of STK36 in HCC.  Results: STK36 expression was elevated in HCC from the TCGA and ICGC databases. IHC and qRT-PCR confirmed the overexpression of STK36 in HCC. STK36 expression had a positive correlation with T stage (tumor stage). STK36 expression was an independent prognostic factor affecting HCC patients’ outcomes. A relationship existed between STK36 expression and the infiltration of immune cells as well as immune checkpoints. Single-cell and spatial transcriptome analyses demonstrated that STK36 was upregulated in HCC. GSEA showed that STK36 was involved in some pathways, including ECM-receptor interaction, cell cycle, etc.  Conclusion: STK36 acts as a potential prognostic index in HCC, serves as a potential biomarker for predicting response to immunotherapy, and provides a rationale for further functional studies.
SN  - 1471-2407
ER  -